newsfilter
← Latest News
GlobeNewswire·

GT Biopharma Oral Presentation at the SITC 2026 Annual Meeting

GT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE®), with a KRAS inhibitor (KRASi),